Search the Newsreel

Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 4,000 Shares of Stock

SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company's stock on August 13th for $30,080, reducing his position by 0.68%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and Xu has made several other sales since early July. …

Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A

BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares

BioNexus Gene Lab Corp (BGLC) announced that its CEO and director, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares. These shares, granted under the company's 2025 Equity Incentive Plan for completed services, were valued at $1.55 per share based …

BioNexus Gene Lab Corp (BGLC) director receives 32,258-share equity award

BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested equity award of 32,258 common shares on August 13, 2026. The award, valued at $1.55 per share, was granted under the company’s 2025 Equity Incentive Plan for completed services, with …

BioNexus Gene Lab Corp (BGLC) director granted 16,129-share fully vested stock award

BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen received a fully vested stock award of 16,129 shares of common stock on August 13, 2026, for services rendered. This equity compensation, granted under the company's 2025 Equity Incentive Plan, had no cash consideration and …

Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 9.99% beneficial ownership stake in enGene Holdings Inc. (NASDAQ: ENGN). This stake includes both common shares and pre-funded warrants, with the exercise of warrants capped at 9.99% ownership due to …

The Bull Case For Dollar General (DG) Could Change Following Management’s Cautious Consumer and Sales Outlook – Learn Why

Dollar General's management has expressed caution regarding consumer spending due to inflation, high gas prices, and reduced SNAP benefits, maintaining an unchanged annual same-store sales growth outlook of 2.2% to 2.7%. This cautious stance from management contrasts with some analysts' more optimistic views based …

RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA)

RA Capital Management and affiliated funds have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Taysha Gene Therapies (TSHA) common stock as of June 30, 2026. This ownership includes common shares and a portion of pre-funded warrants, capped by a …

Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake

WuXi PharmaTech Healthcare Fund I L.P. and its indirect parent WuXi AppTec Co., Ltd. have filed an amended Schedule 13G, disclosing a 3.5% beneficial ownership in Adagene Inc. (ADAG). As of June 30, 2026, they collectively own 2,891,594 ordinary shares, held in the form …

Diana Shipping withdraws Genco bid as takeover terms hit a roadblock

Bjoern Wylezich Diana Shipping (DSX [https://seekingalpha.com/symbol/DSX]) announced on Friday that it has withdrawn its offer to acquire the remaining shares of Genco Shipping & Trading (GNK [https://seekingalpha.com/symbol/GNK]) after the companies failed to agree on deal terms. The company's withdrawn offer [https://seekingalpha.com/pr/20620174-diana-shipping-inc-withdraws-offer-to-acquire-genco-shipping-and-trading-following-genco] included $24.80 in …

BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake

Glenview Capital Management and Larry Robbins have reported that they no longer hold a significant ownership stake in Myriad Genetics (MYGN). An SEC filing (SCHEDULE 13G/A) indicates that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the outstanding common …

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise

MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …

Global X Management (GEL) reports 6.32% beneficial stake in Genesis Energy units

Global X Management Company LLC has reported a beneficial ownership of 7,722,608 common units in Genesis Energy, L.P., which constitutes a 6.32% stake. This ownership is managed through its role as an investment adviser to the Global X MLP ETF. The acquisition was part …

Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes

Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of …

Genpact (NYSE: G) CFO sells 5,900 shares, retains 176,027 holding

Genpact LTD's Chief Financial Officer, Michael Hal Weiner, sold 5,900 Common Shares on August 13, 2026, at a price of $34.04 per share. Following this transaction, Weiner directly holds 176,027 Common Shares, including 1,591 shares acquired through the Genpact Employee Stock Purchase Plan (ESPP). …

Company G (G) insider plans NYSE sale of 14,972 shares via Morgan Stanley

An insider at Company G (G) has filed a Form 144 to sell 14,972 common shares on the NYSE through Morgan Stanley Smith Barney LLC. The aggregate market value of these shares is approximately $510,558.52, with the planned sale date set for August 14, …

enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power

An amended Schedule 13G/A filing for enGene Holdings Inc. (ENGN) indicates that a group of Venrock-affiliated investment entities and two individuals now report a 0.0% beneficial ownership of the company's Common Shares as of June 30, 2026. This means the group, previously significant holders, …

First Light Asset Management (AXGN) discloses 7.58% Axogen stake for Mathew Arens

First Light Asset Management, LLC and Mathew P. Arens have filed an amended Schedule 13G disclosing their beneficial ownership in Axogen, Inc. First Light Asset Management may be deemed to beneficially own 3,746,380 shares (6.97% of the class), while Mathew P. Arens may be …

Gen Digital Inc. stock underperforms Friday when compared to competitors

Gen Digital Inc. (GEN) stock dropped 3.69% on Friday, closing at $28.48, and underperformed against a declining market where the S&P 500 and Dow Jones also fell. The stock is now 11.25% below its 52-week high of $32.09, which was reached on the same …

Cathay General Bancorp Declares $0.38 Per Share Dividend

Cathay General Bancorp (Nasdaq: CATY) announced that its Board of Directors has declared a cash dividend of $0.38 per common share. The dividend is payable on September 8, 2026, to stockholders of record as of August 28, 2026. Cathay General Bancorp is the holding …

NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens

Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint …

Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing

Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as …

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights …

Diana Shipping Inc. 撤回了收購 Genco Shipping & Trading 的要約，原因是 Genco 董事會提出了無理要求。

Diana Shipping Inc. 已撤回對 Genco Shipping & Trading 的收購要約，理由是 Genco 董事會提出了不合理的要求。Diana Shipping 認為 Genco 的要求過高且不符合其股東的最佳利益，因此決定終止這項交易。此舉反映了雙方在交易條件上未能達成一致。

Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …

Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Groundbreaking takes place for NexGen Energy’s uranium mine project

NexGen Energy Ltd. has officially started construction on its Rook I uranium project in northwest Saskatchewan, marking a significant milestone after years of planning and engagement. The $2.2 billion project is expected to produce 30 million pounds of uranium annually and aims to create …

Genasys Inc. remains a Hold due to unprofitable core business outside Puerto Rico project.

Genasys Inc. is currently rated as a Hold because its core business is unprofitable, despite a temporary boost from a Puerto Rico project. This project is now paused due to issues with receivables and liquidity, exposing the company's weak financial fundamentals. Outside of Puerto …

Genasys Ex-Puerto Rico Quarter Shows How Dire Its Situation Is (NASDAQ:GNSS)

Genasys Inc. (GNSS) is rated a Hold due to its core business being deeply unprofitable outside of the Puerto Rico project. While recent profitability stemmed from this project, liquidity issues have paused it, revealing weak fundamentals. The company faces a strained balance sheet, costly …

Should I Buy NXE (NexGen Energy Ltd.) | AI Analysis, Technical & News Insights

IGIC|International General Insurance Holdings Ltd|Price:27.260|Chg%:+0.350

This article provides a detailed financial overview of International General Insurance Holdings Ltd (IGIC), including its live stock price, key figures, and technical analysis. The company, based in Jordan, specializes in commercial insurance and reinsurance across various segments. Analysts currently rate IGIC as a …

Cogent Communications (NASDAQ:CCOI) Trading 7.5% Higher - Here's Why

Cogent Communications (NASDAQ:CCOI) shares rose 7.5% in mid-day trading despite recent analyst downgrades and a pending securities class-action lawsuit. Analysts have lowered price targets, with a consensus "Hold" rating and an average target of $21.05. The lawsuit alleges misleading disclosures regarding demand, growth, and …

Precigen (NASDAQ:PGEN) Trading Down 5.5% - What's Next?

Precigen (NASDAQ:PGEN) saw its shares drop by 5.5% despite reporting stronger-than-expected quarterly results, with EPS of $0.05 against an estimated loss of $0.01, and revenue soaring by 6,322.7% year-over-year to $54.98 million. The biotechnology company maintains a "Moderate Buy" consensus rating with an average …

T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership

T. Rowe Price Associates, Inc. has disclosed a beneficial ownership of 2,675,457 argenx SE ADRs as of June 30, 2026, representing a 4.3% stake. The firm holds sole voting power over 2,649,465 ADRs and sole dispositive power over all 2,675,457 ADRs, explicitly denying beneficial …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …